Nasopharyngeal Cancer - Pipeline Review, H2 2013


#172067

60pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Nasopharyngeal Cancer Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Nasopharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer. Nasopharyngeal Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Nasopharyngeal Cancer.
  • A review of the Nasopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Nasopharyngeal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nasopharyngeal Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Nasopharyngeal Cancer 8
Nasopharyngeal Cancer Therapeutics under Development by Companies 10
Nasopharyngeal Cancer Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Nasopharyngeal Cancer Therapeutics Products under Development by Companies 16
Nasopharyngeal Cancer Therapeutics Products under Investigation by Universities/Institutes 17
Companies Involved in Nasopharyngeal Cancer Therapeutics Development 18
Gilead Sciences, Inc. 18
Merck & Co., Inc. 19
Cyclacel Pharmaceuticals Inc. 20
Jiangsu Hengrui Medicine Co., Ltd. 21
Coridon Pty Ltd 22
Nasopharyngeal Cancer Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
MK-2206 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CYC-202 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
EBV-Specific T-Lymphocytes - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
bevacizumab + [cisplatin] + [fluorouracil] + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
nimotuzumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes + [carboplatin]+ [gemcitabine] - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Modified Vaccinia Ankara Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Famitinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Famitinib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cytokine-Induced Killer Cells + [cisplatin] + [gemcitabine] - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Epstein Barr Virus Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Imidazoles - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
EBV-Specific CTL Therapy - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Nasopharyngeal Cancer Therapeutics Drug Profile Updates 51
Nasopharyngeal Cancer Therapeutics - Dormant Products 53
Nasopharyngeal Cancer Product Development Milestones 54
Featured News & Press Releases 54
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 54
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting 55
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR 55
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer 56
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial 57
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies 57

Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

Number of Products Under Development for Nasopharyngeal Cancer, H2 2013 8
Products under Development for Nasopharyngeal Cancer Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Gilead Sciences, Inc., H2 2013 18
Merck & Co., Inc., H2 2013 19
Cyclacel Pharmaceuticals Inc., H2 2013 20
Jiangsu Hengrui Medicine Co., Ltd., H2 2013 21
Coridon Pty Ltd, H2 2013 22
Assessment by Monotherapy Products, H2 2013 23
Assessment by Combination Products, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 28
Nasopharyngeal Cancer Therapeutics Drug Profile Updates 51
Nasopharyngeal Cancer Therapeutics Dormant Products 53
Number of Products under Development for Nasopharyngeal Cancer, H2 2013 8
Products under Development for Nasopharyngeal Cancer Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 11
Late Stage Products, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Discovery and Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 23
Assessment by Combination Products, H2 2013 24
Assessment by Route of Administration, H2 2013 25
Assessment by Stage and Route of Administration, H2 2013 26
Assessment by Molecule Type, H2 2013 27
Assessment by Stage and Molecule Type, H2 2013 28